A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study
Authors:
- 3 February 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 37 (35) , 2722-2730
Abstract
Pharmacodynamic (PD) studies comparing prasugrel and ticagrelor have reached inconsistent findings. Therefore, a comprehensive investigation comparing the PD effects of prasugrel vs. ticagrelor after switching from clopidogrel therapy, exploring both loading dose (LD) and maintenance dose (MD) regimens represented the aim of this study. Patients (n = 110) with coronary artery disease were randomized to prasugrel (60 mg LD/10 mg MD q.d.) or ticagrelor (180 mg LD/90 mg MD b.i.d) therapy for 1 week. Pharmacodynamic assessments were conducted using three assays (vasodilator-stimulated phosphoprotein, VerifyNow P2Y12, and light transmittance aggregometry, LTA) at baseline, 30 min, 2, 24 h, and 1 week. The impact of initiating ticagrelor MD 12 vs. 24 h after LD administration was also assessed. Switching clopidogrel-treated patients to an LD of prasugrel or ticagrelor was associated with a reduction in platelet reactivity at 30 min and was sustained at all time points up to 1 week with the MD (P < 0.001 for all assays). Platelet reactivity was similar with prasugrel and ticagrelor with all assays at 30 min, 2 h, and 1 week (P > 0.05 for all time points), with the exception of LTA at 30 min (lower with prasugrel; P = 0.003). At 24 h, platelet reactivity was lower among patients initiating ticagrelor MD after 12 vs. 24 h post-LD. Rates of high platelet reactivity (HPR) were markedly reduced and similar between groups. Prasugrel and ticagrelor exert similar levels of P2Y12 inhibition achieving more potent PD effects and reduced HPR rates compared with clopidogrel which are reached promptly following LD and sustained with MD. NCT01852175.Keywords
Funding Information
- Institutional Grant of the University of Florida College of Medicine
- Jacksonville
This publication has 28 references indexed in Scilit:
- High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysisJournal of Thrombosis and Haemostasis, 2015
- Meta-Analysis of Direct and Indirect Comparison of Ticagrelor and Prasugrel Effects on Platelet ReactivityThe American Journal of Cardiology, 2015
- Novel antiplatelet agents in acute coronary syndromeNature Reviews Cardiology, 2014
- Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery DiseaseJACC, 2014
- Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and BleedingJACC, 2013
- Relationship between post‐treatment platelet reactivity and ischemic and bleeding events at 1‐year follow‐up in patients receiving prasugrelJournal of Thrombosis and Haemostasis, 2012
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2009
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Variability in Individual Responsiveness to ClopidogrelJACC, 2007
- Design and analysis of pilot studies: recommendations for good practiceJournal of Evaluation in Clinical Practice, 2004